Korsana Biosciences, Inc. (KRSA) vs NervGen Pharma Corp. Common stock (NGEN)
A side-by-side comparison of Korsana Biosciences, Inc. and NervGen Pharma Corp. Common stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
KRSA
Korsana Biosciences, Inc.
$31.12HealthcareDelayed quote: Oct 6, 2026, 11:05 AM EDT
NGEN
NervGen Pharma Corp. Common stock
$1.80HealthcareDelayed quote: Oct 6, 2026, 11:05 AM EDT
Total return — KRSA vs NGEN
growth of $100 · dividends reinvested · last 1yKRSA +155.1% (+155.1%/yr)NGEN -57.6% (-57.6%/yr)KRSA compounded faster over this window
Log scale — wide-divergence pair
KRSA NGEN
KRSA vs NGEN: by the numbers
- •NGEN is the larger company ($148M vs $146M market cap).
- •Both run net losses; NGEN's is the smaller (0.00% vs -353.00% net margin).
Metrics side by side
Valuation
| Metric | KRSA | NGEN |
|---|---|---|
| P/S ratio | 76.68 | N/A |
| P/B ratio | 28.64 | 12.11 |
Profitability
| Metric | KRSA | NGEN |
|---|---|---|
| Gross margin | 100.00% | 0.00% |
| Operating margin | -239.78% | 0.00% |
| Net margin | -353.00% | 0.00% |
| ROE | -131.85% | -397.38% |
| ROIC | -134.15% | -223.90% |
Growth (annualized)
| Metric | KRSA | NGEN |
|---|---|---|
| Revenue CAGR (5Y) | -11.98% | N/A |
| Total return CAGR (5Y) | -40.41% | N/A |
Go deeper
Dig into the metrics
Korsana Biosciences ROENervGen Pharma Corp. Common stock ROEKorsana Biosciences operating marginNervGen Pharma Corp. Common stock operating marginKorsana Biosciences revenue growthNervGen Pharma Corp. Common stock revenue growthKorsana Biosciences free cash flowNervGen Pharma Corp. Common stock free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.